Tretynoina: interakcje
Tretynoina (Retin-A, Renova, Altreno), retinoid: 106 udokumentowanych interakcji w indeksowanych przez nas etykietach FDA i kartach informacyjnych. Poważne: 96, umiarkowane: 9, niewielkie: 1, pary, dla których etykieta nie zgłasza istotnej interakcji: 0. Każda pozycja poniżej cytuje zdanie, na którym się opiera. Ta strona leku to punkt wyjścia, a nie rozstrzygnięcie dla indywidualnej sytuacji.
Interakcje z etykiety
Poważne interakcje (96)
Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (etykieta leku Tretynoina, Przeciwwskazania)
Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (etykieta leku Tretynoina, Przeciwwskazania)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (etykieta leku Tretynoina, Przeciwwskazania)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
• Leukocytosis: Consider administering cytoreductive chemotherapy (including an anthracycline if not contraindicated or hydroxyurea) with tretinoin capsules in the setting of leukocytosis, as clinically indicated. (etykieta leku Tretynoina, Ostrzeżenia i środki ostrożności)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (etykieta leku Tretynoina, Przeciwwskazania)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
Avoid concomitant use of tretinoin capsules and anti-fibrinolytic agents, such as tranexamic acid, aminocaproic acid or aprotinin [see Drug Interactions ( 7.4 )] . (etykieta leku Tretynoina, Ostrzeżenia i środki ostrożności)
Avoid concomitant use of tretinoin capsules and anti-fibrinolytic agents, such as tranexamic acid, aminocaproic acid or aprotinin [see Drug Interactions ( 7.4 )] . (etykieta leku Tretynoina, Ostrzeżenia i środki ostrożności)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use of isotretinoin and EMROSI because isotretinoin, a systemic retinoid, is also known to cause idiopathic intracranial hypertension. (etykieta leku Minocyklina, Ostrzeżenia i środki ostrożności)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Concomitant use of isotretinoin and tetracycline should be avoided because isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri. (etykieta leku Tetracyklina, Ostrzeżenia)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)
At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etykieta leku Tretynoina, Ostrzeżenie w ramce)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (etykieta leku Tretynoina, Interakcje z innymi lekami)
Umiarkowane interakcje (9)
- Chlorek wapniaUmiarkowana
Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (etykieta leku Chlorek wapnia, Interakcje z innymi lekami)
The concomitant use of other products (e.g., tetracyclines) that can cause intracranial hypertension may increase the risk. (etykieta leku Tretynoina, Ostrzeżenia i środki ostrożności)
The concomitant use of other products (e.g., tetracyclines) that can cause intracranial hypertension may increase the risk. (etykieta leku Tretynoina, Ostrzeżenia i środki ostrożności)
- Eleksakaftor + tezakaftor + iwakaftorUmiarkowana
Patients with elevated vitamin A levels may be at increased risk. (etykieta leku Eleksakaftor + tezakaftor + iwakaftor, Ostrzeżenia i środki ostrożności)
Monitor patients receiving XATMEP with other potential hepatotoxins (e.g., azathioprine, retinoids, and sulfasalazine) for possible signs of hepatotoxicity. (etykieta leku Metotreksat, Interakcje z innymi lekami)
- OrlistatUmiarkowana
The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time [see Clinical Pharmacology (12.3) , and Warnings and Precautions (5.1) ] . (etykieta leku Orlistat, Interakcje z innymi lekami)
Hepatotoxicity: Elevated aspartate aminotransferase (AST), alkaline phosphatase and serum bilirubin have occurred in patients with newly-diagnosed low-risk APL treated with arsenic trioxide in combination with tretinoin. (etykieta leku Trójtlenek arsenu, Ostrzeżenia i środki ostrożności)
The concomitant use of other products (e.g., tetracyclines) that can cause intracranial hypertension may increase the risk. (etykieta leku Tretynoina, Ostrzeżenia i środki ostrożności)
The concomitant use of other products (e.g., tetracyclines) that can cause intracranial hypertension may increase the risk. (etykieta leku Tretynoina, Ostrzeżenia i środki ostrożności)
Wzmianki o niewielkim znaczeniu (1)
- Glukonian wapniaNiewielka
Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (etykieta leku Glukonian wapnia, Interakcje z innymi lekami)
Sprawdź, jak Tretynoina łączy się ze wszystkim, co przyjmujesz. Dodaj całą listę; wszystkie pary są sprawdzane jednocześnie.
Otwórz w wyszukiwarceTo nie jest porada medyczna. Stopień nasilenia odzwierciedla sformułowania etykiety, a nie indywidualne okoliczności. Oznaczenie „poważna” może dotyczyć połączenia stosowanego rutynowo pod nadzorem, a „niewielka” może mieć znaczenie przy dużych dawkach. Należy zapytać farmaceutę.